Toggle menu

ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study

Start date:
March 2020
Co-ordinated by:
University of Oxford
Main trial site:
Royal Infirmary of Edinburgh, Western General Hospital, St John's Hospital

Infectious disease is the single biggest cause of death worldwide. New infectious agents, such as the SARS, MERS and other novel coronavirus’ require investigation to understand pathogen biology and pathogenesis in the host. Even for known infections, resistance to antimicrobial therapies is widespread, and treatments to control potentially deleterious host responses are lacking.

The ISARIC study aims to develop a mechanistic understanding of disease processes, so that risk factors for severe illness can be identified and treatments can be developed.

When patients are confirmed to have corona virus, the research team will ask them to participate into this study. The participant will be consenting to provide blood, urine and faecal samples throughout their admission at day 1, 3 and 9, with a final follow up completed at day 28.

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Rachel O'Brien

Lead Research Nurse

Nicky Freeman

Senior Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Emily Godden

Senior Research Nurse - Renal/Acute Medicine

Nicholas Fethers

Research Administrator

Michelle Coakley

Senior Research Nurse - Stroke/Neurosurgery

Julia Grahamslaw

Lead Research Nurse

More EMERGE Trials

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more

IONA Study

Identification of Novel Psychoactive Substances (IONA)

Early diagnosis is central to improving outcomes for patients with cancer. For cancers without specific risk factors, or with no screening programs are difficult to diagnose and patients often present with non-specific symptoms. Unfortunately this means that these patients are often diagnosed late on in the development of the disease and treatment options are reduced.

Read more